Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is March 27, 2025, covering a share repurchase executed on March 26, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for the transaction are as follows:
- Shares Purchased: 847,000 ordinary shares.
- Price Range: Lowest price paid was 1,454.50 GBp; highest price paid was 1,481.50 GBp.
- Volume-Weighted Average Price (VWAP): 1,471.84 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: Following this purchase, GSK holds 184,789,390 ordinary shares in treasury.
- Shares in Issue: 4,130,425,456 ordinary shares (excluding treasury shares).
- Total Voting Rights: 4,130,425,456.
The filing text does not provide values for revenue, profit, cash flow, margins, or debt.
Material Changes
Since the commencement of the current buyback programme on February 24, 2025, GSK has purchased a total of 15,719,087 ordinary shares. The March 26 transaction represents the most recent activity within this programme. There are no other material changes to the company's financial position or operations disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced as being described on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F. No new guidance or management commentary regarding future financial performance is provided in this document.
Investor Verification Checklist
- Verify the total number of treasury shares held (184,789,390) against the latest Form 20-F or quarterly reports.
- Confirm the remaining capacity under the current buyback programme authorized on February 24, 2025.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors referenced in the cautionary statement.
- Monitor subsequent filings for updates on the buyback programme progress and total shares repurchased.